New horizons in the treatment of cystic fibrosis
Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA‐dependent, ATP‐requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR...
Saved in:
| Published in: | British journal of pharmacology Vol. 163; no. 1; pp. 173 - 183 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
Oxford, UK
Blackwell Publishing Ltd
01-05-2011
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA‐dependent, ATP‐requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR (cystic fibrosis transmembrane conductance regulator). There are currently over 1700 known mutations affecting CFTR, many of which give rise to a disease phenotype. Around 75% of CF alleles contain the ΔF508 mutation in which a triplet codon has been lost, leading to a missing phenylalanine at position 508 in the protein. This altered protein fails to be trafficked to the correct location in the cell and is generally destroyed by the proteasome. The small amount that does reach the correct location functions poorly. Clearly the cohort of patients with at least one ΔF508 allele are a major target for therapeutic intervention. It is now over two decades since the CF gene was discovered and during this time the properties of CFTR have been intensely investigated. At long last there appears to be progress with the pharmaco‐therapeutic approach. Ongoing clinical trials have produced fascinating results in which clinical benefit appears to have been achieved. To arrive at this point ingenious ways have been devised to screen very large chemical libraries for one of two properties: (i) agents promoting trafficking of mutant CFTR to, and insertion into the membrane, and known as correctors or (ii) agents which activate appropriately located mutant CFTR, known as potentiators. The best compounds emerging from these programmes are then used as chemical scaffolds to synthesize other compounds with appropriate pharmaceutical properties, hopefully with their pharmacological activity maintained or even enhanced. In summary, this approach attempts to make the mutant CFTR function in place of the real CFTR. A major function of CFTR in healthy airways is to maintain an adequate airway surface liquid (ASL) layer. In CF the position is further confounded since epithelial sodium channels (ENaC) are no longer regulated and transport salt and water out of the airways to exacerbate the lack of ASL. Thus an additional possibility for treatment of CF is to use agents that inhibit ENaC either alone or as adjuncts to CFTR correctors and/or potentiators. Yet a further way in which a pharmacological approach to CF can be considered is to recruit alternative chloride channels, such as calcium‐activated chloride channel (CaCC), to act as surrogates for CFTR. A number of P2Y2 receptor agonists have been investigated that operate by increasing Ca2+i which in turn activates CaCC. Some of these compounds are currently in clinical trials. The knowledge base surrounding the structure and function of CFTR that has accumulated in the last 20 years is impressive. Translational research feeding from this is now yielding compounds that provide real prospects for a pharmacotherapy for this disease.
LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue‐1 |
|---|---|
| AbstractList | Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA‐dependent, ATP‐requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR (cystic fibrosis transmembrane conductance regulator). There are currently over 1700 known mutations affecting CFTR, many of which give rise to a disease phenotype. Around 75% of CF alleles contain the ΔF508 mutation in which a triplet codon has been lost, leading to a missing phenylalanine at position 508 in the protein. This altered protein fails to be trafficked to the correct location in the cell and is generally destroyed by the proteasome. The small amount that does reach the correct location functions poorly. Clearly the cohort of patients with at least one ΔF508 allele are a major target for therapeutic intervention. It is now over two decades since the CF gene was discovered and during this time the properties of CFTR have been intensely investigated. At long last there appears to be progress with the pharmaco‐therapeutic approach. Ongoing clinical trials have produced fascinating results in which clinical benefit appears to have been achieved. To arrive at this point ingenious ways have been devised to screen very large chemical libraries for one of two properties: (i) agents promoting trafficking of mutant CFTR to, and insertion into the membrane, and known as correctors or (ii) agents which activate appropriately located mutant CFTR, known as potentiators. The best compounds emerging from these programmes are then used as chemical scaffolds to synthesize other compounds with appropriate pharmaceutical properties, hopefully with their pharmacological activity maintained or even enhanced. In summary, this approach attempts to make the mutant CFTR function in place of the real CFTR. A major function of CFTR in healthy airways is to maintain an adequate airway surface liquid (ASL) layer. In CF the position is further confounded since epithelial sodium channels (ENaC) are no longer regulated and transport salt and water out of the airways to exacerbate the lack of ASL. Thus an additional possibility for treatment of CF is to use agents that inhibit ENaC either alone or as adjuncts to CFTR correctors and/or potentiators. Yet a further way in which a pharmacological approach to CF can be considered is to recruit alternative chloride channels, such as calcium‐activated chloride channel (CaCC), to act as surrogates for CFTR. A number of P2Y2 receptor agonists have been investigated that operate by increasing Ca2+i which in turn activates CaCC. Some of these compounds are currently in clinical trials. The knowledge base surrounding the structure and function of CFTR that has accumulated in the last 20 years is impressive. Translational research feeding from this is now yielding compounds that provide real prospects for a pharmacotherapy for this disease.
LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue‐1 Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA-dependent, ATP-requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR (cystic fibrosis transmembrane conductance regulator). There are currently over 1700 known mutations affecting CFTR, many of which give rise to a disease phenotype. Around 75% of CF alleles contain the [Delta]F508 mutation in which a triplet codon has been lost, leading to a missing phenylalanine at position 508 in the protein. This altered protein fails to be trafficked to the correct location in the cell and is generally destroyed by the proteasome. The small amount that does reach the correct location functions poorly. Clearly the cohort of patients with at least one [Delta]F508 allele are a major target for therapeutic intervention. It is now over two decades since the CF gene was discovered and during this time the properties of CFTR have been intensely investigated. At long last there appears to be progress with the pharmaco-therapeutic approach. Ongoing clinical trials have produced fascinating results in which clinical benefit appears to have been achieved. To arrive at this point ingenious ways have been devised to screen very large chemical libraries for one of two properties: (i) agents promoting trafficking of mutant CFTR to, and insertion into the membrane, and known as correctors or (ii) agents which activate appropriately located mutant CFTR, known as potentiators. The best compounds emerging from these programmes are then used as chemical scaffolds to synthesize other compounds with appropriate pharmaceutical properties, hopefully with their pharmacological activity maintained or even enhanced. In summary, this approach attempts to make the mutant CFTR function in place of the real CFTR. A major function of CFTR in healthy airways is to maintain an adequate airway surface liquid (ASL) layer. In CF the position is further confounded since epithelial sodium channels (ENaC) are no longer regulated and transport salt and water out of the airways to exacerbate the lack of ASL. Thus an additional possibility for treatment of CF is to use agents that inhibit ENaC either alone or as adjuncts to CFTR correctors and/or potentiators. Yet a further way in which a pharmacological approach to CF can be considered is to recruit alternative chloride channels, such as calcium-activated chloride channel (CaCC), to act as surrogates for CFTR. A number of P2Y2 receptor agonists have been investigated that operate by increasing Ca2+i which in turn activates CaCC. Some of these compounds are currently in clinical trials. The knowledge base surrounding the structure and function of CFTR that has accumulated in the last 20 years is impressive. Translational research feeding from this is now yielding compounds that provide real prospects for a pharmacotherapy for this disease. LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue-1 [PUBLICATION ABSTRACT] Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA-dependent, ATP-requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR (cystic fibrosis transmembrane conductance regulator). There are currently over 1700 known mutations affecting CFTR, many of which give rise to a disease phenotype. Around 75% of CF alleles contain the ΔF508 mutation in which a triplet codon has been lost, leading to a missing phenylalanine at position 508 in the protein. This altered protein fails to be trafficked to the correct location in the cell and is generally destroyed by the proteasome. The small amount that does reach the correct location functions poorly. Clearly the cohort of patients with at least one ΔF508 allele are a major target for therapeutic intervention. It is now over two decades since the CF gene was discovered and during this time the properties of CFTR have been intensely investigated. At long last there appears to be progress with the pharmaco-therapeutic approach. Ongoing clinical trials have produced fascinating results in which clinical benefit appears to have been achieved. To arrive at this point ingenious ways have been devised to screen very large chemical libraries for one of two properties: (i) agents promoting trafficking of mutant CFTR to, and insertion into the membrane, and known as correctors or (ii) agents which activate appropriately located mutant CFTR, known as potentiators. The best compounds emerging from these programmes are then used as chemical scaffolds to synthesize other compounds with appropriate pharmaceutical properties, hopefully with their pharmacological activity maintained or even enhanced. In summary, this approach attempts to make the mutant CFTR function in place of the real CFTR. A major function of CFTR in healthy airways is to maintain an adequate airway surface liquid (ASL) layer. In CF the position is further confounded since epithelial sodium channels (ENaC) are no longer regulated and transport salt and water out of the airways to exacerbate the lack of ASL. Thus an additional possibility for treatment of CF is to use agents that inhibit ENaC either alone or as adjuncts to CFTR correctors and/or potentiators. Yet a further way in which a pharmacological approach to CF can be considered is to recruit alternative chloride channels, such as calcium-activated chloride channel (CaCC), to act as surrogates for CFTR. A number of P2Y(2) receptor agonists have been investigated that operate by increasing Ca(2+)(i) which in turn activates CaCC. Some of these compounds are currently in clinical trials. The knowledge base surrounding the structure and function of CFTR that has accumulated in the last 20 years is impressive. Translational research feeding from this is now yielding compounds that provide real prospects for a pharmacotherapy for this disease. Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA‐dependent, ATP‐requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR (cystic fibrosis transmembrane conductance regulator). There are currently over 1700 known mutations affecting CFTR, many of which give rise to a disease phenotype. Around 75% of CF alleles contain the ΔF508 mutation in which a triplet codon has been lost, leading to a missing phenylalanine at position 508 in the protein. This altered protein fails to be trafficked to the correct location in the cell and is generally destroyed by the proteasome. The small amount that does reach the correct location functions poorly. Clearly the cohort of patients with at least one ΔF508 allele are a major target for therapeutic intervention. It is now over two decades since the CF gene was discovered and during this time the properties of CFTR have been intensely investigated. At long last there appears to be progress with the pharmaco‐therapeutic approach. Ongoing clinical trials have produced fascinating results in which clinical benefit appears to have been achieved. To arrive at this point ingenious ways have been devised to screen very large chemical libraries for one of two properties: (i) agents promoting trafficking of mutant CFTR to, and insertion into the membrane, and known as correctors or (ii) agents which activate appropriately located mutant CFTR, known as potentiators. The best compounds emerging from these programmes are then used as chemical scaffolds to synthesize other compounds with appropriate pharmaceutical properties, hopefully with their pharmacological activity maintained or even enhanced. In summary, this approach attempts to make the mutant CFTR function in place of the real CFTR. A major function of CFTR in healthy airways is to maintain an adequate airway surface liquid (ASL) layer. In CF the position is further confounded since epithelial sodium channels (ENaC) are no longer regulated and transport salt and water out of the airways to exacerbate the lack of ASL. Thus an additional possibility for treatment of CF is to use agents that inhibit ENaC either alone or as adjuncts to CFTR correctors and/or potentiators. Yet a further way in which a pharmacological approach to CF can be considered is to recruit alternative chloride channels, such as calcium‐activated chloride channel (CaCC), to act as surrogates for CFTR. A number of P2Y 2 receptor agonists have been investigated that operate by increasing Ca 2+ i which in turn activates CaCC. Some of these compounds are currently in clinical trials. The knowledge base surrounding the structure and function of CFTR that has accumulated in the last 20 years is impressive. Translational research feeding from this is now yielding compounds that provide real prospects for a pharmacotherapy for this disease. LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue‐1 Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA-dependent, ATP-requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR (cystic fibrosis transmembrane conductance regulator). There are currently over 1700 known mutations affecting CFTR, many of which give rise to a disease phenotype. Around 75% of CF alleles contain the ΔF508 mutation in which a triplet codon has been lost, leading to a missing phenylalanine at position 508 in the protein. This altered protein fails to be trafficked to the correct location in the cell and is generally destroyed by the proteasome. The small amount that does reach the correct location functions poorly. Clearly the cohort of patients with at least one ΔF508 allele are a major target for therapeutic intervention. It is now over two decades since the CF gene was discovered and during this time the properties of CFTR have been intensely investigated. At long last there appears to be progress with the pharmaco-therapeutic approach. Ongoing clinical trials have produced fascinating results in which clinical benefit appears to have been achieved. To arrive at this point ingenious ways have been devised to screen very large chemical libraries for one of two properties: (i) agents promoting trafficking of mutant CFTR to, and insertion into the membrane, and known as correctors or (ii) agents which activate appropriately located mutant CFTR, known as potentiators. The best compounds emerging from these programmes are then used as chemical scaffolds to synthesize other compounds with appropriate pharmaceutical properties, hopefully with their pharmacological activity maintained or even enhanced. In summary, this approach attempts to make the mutant CFTR function in place of the real CFTR. A major function of CFTR in healthy airways is to maintain an adequate airway surface liquid (ASL) layer. In CF the position is further confounded since epithelial sodium channels (ENaC) are no longer regulated and transport salt and water out of the airways to exacerbate the lack of ASL. Thus an additional possibility for treatment of CF is to use agents that inhibit ENaC either alone or as adjuncts to CFTR correctors and/or potentiators. Yet a further way in which a pharmacological approach to CF can be considered is to recruit alternative chloride channels, such as calcium-activated chloride channel (CaCC), to act as surrogates for CFTR. A number of P2Y 2 receptor agonists have been investigated that operate by increasing Ca 2+ i which in turn activates CaCC. Some of these compounds are currently in clinical trials. The knowledge base surrounding the structure and function of CFTR that has accumulated in the last 20 years is impressive. Translational research feeding from this is now yielding compounds that provide real prospects for a pharmacotherapy for this disease. |
| Author | Cuthbert, AW |
| Author_xml | – sequence: 1 givenname: AW surname: Cuthbert fullname: Cuthbert, AW |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21108631$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU1P3DAQhq0KVBbKX6gi9cAp25l1_JFDkQCVDwnRHsrZchy761U2pna2sPx6nC6sKCd8seX3mVcz8-6TnT70lpACYYr5fF1MsRK8ZFTidAb5FxCpmD58IJOtsEMmACBKRCn3yH5KC4AsCvaR7M0QQXKKEwI39r6Yh-gfQ58K3xfD3BZDtHpY2n4ogivMOg3eFM43MSSfPpFdp7tkD5_vA3J7_v3X2WV5_ePi6uzkujQMUJS8clrUFdONNVTyxjXcCFbLGhwH2QrJHbS1QaBMcyadNVjTVqOrrKCMtfSAHG9871bN0rYmdxN1p-6iX-q4VkF79b_S-7n6Hf4qCpJJwbPB0bNBDH9WNg1q6ZOxXad7G1ZJSY4zYChpJr-8IRdhFfs8nULGqqoWIOtMyQ1l8h5StG7bC4IaU1ELNS5fjctXYyrqXyrqIZd-fj3LtvAlhgx82wD3vrPrdxur05-X44s-AaEknD8 |
| CitedBy_id | crossref_primary_10_1080_21678707_2018_1409110 crossref_primary_10_1002_ppul_26787 crossref_primary_10_1002_ppul_22567 crossref_primary_10_1113_jphysiol_2013_253955 crossref_primary_10_1063_5_0116648 crossref_primary_10_5812_compreped_122110 crossref_primary_10_1016_j_bbagen_2014_07_010 crossref_primary_10_1111_j_1476_5381_2011_01239_x crossref_primary_10_1016_j_molmed_2011_10_003 crossref_primary_10_1164_rccm_201510_1922OC crossref_primary_10_3390_ijms21218084 crossref_primary_10_1007_s40778_020_00175_1 crossref_primary_10_1016_j_ejpb_2016_04_009 crossref_primary_10_1371_journal_pone_0215786 crossref_primary_10_1098_rsbm_2019_0036 crossref_primary_10_1089_scd_2011_0041 crossref_primary_10_1242_jcs_093260 crossref_primary_10_1038_s41598_021_99184_1 crossref_primary_10_1016_j_ijpam_2015_05_006 crossref_primary_10_1084_jem_20121248 crossref_primary_10_1002_adma_202308029 crossref_primary_10_3109_10409238_2012_694846 crossref_primary_10_4155_fmc_11_157 crossref_primary_10_1111_bph_12017 crossref_primary_10_1016_j_coph_2018_09_007 crossref_primary_10_1124_pr_111_005009 crossref_primary_10_1002_cmdc_201200311 crossref_primary_10_1038_onc_2012_251 crossref_primary_10_1085_jgp_201411179 crossref_primary_10_3390_genes10030183 crossref_primary_10_1002_jcp_25823 crossref_primary_10_1111_j_1476_5381_2012_02041_x crossref_primary_10_1038_srep36806 crossref_primary_10_1016_j_ejmech_2017_12_030 crossref_primary_10_1186_s12931_023_02630_z crossref_primary_10_1152_ajpcell_00196_2012 crossref_primary_10_1007_s00018_021_04030_2 crossref_primary_10_1517_13543776_2013_829454 crossref_primary_10_1242_jcs_240390 crossref_primary_10_1152_ajpcell_00250_2013 crossref_primary_10_3390_biom13020350 crossref_primary_10_1016_j_ejmech_2015_05_030 crossref_primary_10_1021_jp3081029 crossref_primary_10_1074_jbc_M111_332031 crossref_primary_10_1111_bph_12447 crossref_primary_10_1002_jgm_2748 |
| Cites_doi | 10.1378/chest.07-0288 10.1152/ajpcell.00528.2003 10.1124/jpet.104.071886 10.1056/NEJM199108223250802 10.1038/nm0496-467 10.1085/jgp.20028598 10.1038/sj.bjp.0705846 10.1074/jbc.274.39.27415 10.1124/jpet.102.035485 10.1172/JCI24898 10.1085/jgp.200509468 10.1152/physrev.00007.2002 10.3109/09687689309150258 10.1111/j.1476-5381.1978.tb07783.x 10.1152/ajpcell.1999.276.4.C827 10.1039/B810471A 10.1111/j.1476-5381.2010.01058.x 10.1007/s00424-002-0957-z 10.1034/j.1399-3003.1999.14c32.x 10.1056/NEJMoa022170 10.1074/jbc.M512766200 10.1016/S0092-8674(00)81724-9 10.2174/157339609787587555 10.1007/s00424-004-1356-4 10.1056/NEJMoa043900 10.1016/j.autneu.2007.01.008 10.1152/ajpcell.1995.268.4.C886 10.1056/NEJM199004263221704 10.1016/S0968-0896(03)00435-8 10.1164/ajrccm.157.6.9709043 10.1165/rcmb.2008-0384OC 10.1164/rccm.200608-1238OC 10.1073/pnas.131087598 10.1074/jbc.M107257200 10.1152/ajpcell.1990.259.3.C450 10.1021/mp0500521 10.1074/jbc.M205932200 10.1073/pnas.0904709106 10.1124/jpet.107.130443 10.1124/mol.110.065862 10.1152/ajpcell.00417.2002 10.1053/j.gastro.2009.05.037 10.1074/jbc.M006764200 10.1002/ppul.20183 10.1152/ajplung.1999.277.4.L694 10.1152/ajpcell.00397.2003 10.1124/jpet.108.148155 10.1074/jbc.M101892200 10.1038/nm1028 10.1021/jm051134w 10.1152/ajplung.2001.281.2.L458 10.1152/ajplung.00169.2005 10.1146/annurev.physiol.010908.163108 10.1038/358761a0 10.1085/jgp.201010399 10.1074/jbc.M303098200 10.1124/mol.105.015149 10.1242/jcs.114.22.4073 10.1016/S0021-9258(19)78079-X 10.1152/ajplung.2001.281.1.L16 10.1126/science.2475911 10.1016/S0070-2153(06)78002-4 10.1183/09031936.02.00017202 10.1016/0005-2736(92)90345-M 10.1378/chest.07-2294 10.1152/ajplung.90636.2008 10.1016/j.ejphar.2005.04.037 |
| ContentType | Journal Article |
| Copyright | 2010 The Author. British Journal of Pharmacology © 2010 The British Pharmacological Society 2010 The Author. British Journal of Pharmacology © 2010 The British Pharmacological Society. British Journal of Pharmacology © 2011 The British Pharmacological Society |
| Copyright_xml | – notice: 2010 The Author. British Journal of Pharmacology © 2010 The British Pharmacological Society – notice: 2010 The Author. British Journal of Pharmacology © 2010 The British Pharmacological Society. – notice: British Journal of Pharmacology © 2011 The British Pharmacological Society |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. NAPCQ 7X8 5PM |
| DOI | 10.1111/j.1476-5381.2010.01137.x |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1476-5381 |
| EndPage | 183 |
| ExternalDocumentID | 3407668201 10_1111_j_1476_5381_2010_01137_x 21108631 BPH1137 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .3N .55 .GJ 05W 0R~ 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 3V. 4.4 52U 52V 53G 5GY 6J9 7RV 7X7 8-0 8-1 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 8UM A00 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCUV ABDBF ABPVW ABQWH ABUWG ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFKRA AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB B0M BAFTC BAWUL BBNVY BENPR BFHJK BHBCM BHPHI BKEYQ BMXJE BPHCQ BRXPI BVXVI C45 CAG CCPQU COF CS3 DCZOG DIK DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBC EBD EBS ECV EJD EMB EMK EMOBN ENC ESX EX3 F5P FUBAC FYUFA G-S GODZA GX1 H.X HCIFZ HGLYW HMCUK HYE HZ~ J5H KBYEO LATKE LEEKS LH4 LITHE LK8 LOXES LSO LUTES LW6 LYRES M1P M7P MEWTI MK0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NAPCQ NF~ O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ PROAC PSQYO Q.N Q2X QB0 RIG ROL RPM RWI SJN SUPJJ SV3 TEORI TR2 TUS UKHRP UPT WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WVDHM WXSBR X7M XV2 Y6R YHG ZGI ZXP ZZTAW ~8M ~S- CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7QP 7TK K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c5017-64fa7945abec386bfb6c759890f608d786f0d9c1035a658fec193da1f4e7355d3 |
| IEDL.DBID | RPM |
| ISSN | 0007-1188 |
| IngestDate | Tue Sep 17 21:25:47 EDT 2024 Fri Aug 16 07:55:31 EDT 2024 Tue Nov 19 03:52:07 EST 2024 Thu Nov 21 20:56:14 EST 2024 Sat Sep 28 07:59:33 EDT 2024 Sat Aug 24 01:00:14 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2010 The Author. British Journal of Pharmacology © 2010 The British Pharmacological Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5017-64fa7945abec386bfb6c759890f608d786f0d9c1035a658fec193da1f4e7355d3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://europepmc.org/articles/pmc3085876?pdf=render |
| PMID | 21108631 |
| PQID | 1554497089 |
| PQPubID | 42104 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3085876 proquest_miscellaneous_861205183 proquest_journals_1554497089 crossref_primary_10_1111_j_1476_5381_2010_01137_x pubmed_primary_21108631 wiley_primary_10_1111_j_1476_5381_2010_01137_x_BPH1137 |
| PublicationCentury | 2000 |
| PublicationDate | May 2011 2011-May 2011-05-00 20110501 |
| PublicationDateYYYYMMDD | 2011-05-01 |
| PublicationDate_xml | – month: 05 year: 2011 text: May 2011 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England – name: London |
| PublicationTitle | British journal of pharmacology |
| PublicationTitleAlternate | Br J Pharmacol |
| PublicationYear | 2011 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | 1992; 1107 2004; 287 2004; 286 2009; 41 2005b; 115 2002; 277 2006; 290 2008; 31 1998; 157 2003; 278 2007; 78 2009; 158 2003; 11 1994; 267 1990; 259 1986; 146 1994; 269 1978; 63 2007; 176 2007; 132 2007; 133 1999; 14 1992; 358 2002; 302 2006; 281 2003; 445 2006; 127 1998; 95 2009; 329 1996; 2 2001; 98 2003; 284 2010; 78 2004; 142 2001; 281 2005; 40 2005; 516 2008; 325 2010; 162 2002; 82 2009; 296 1990; 322 1991; 259 2006; 354 2009; 137 2001; 276 2004; 10 2005a; 68 2003; 349 1976; 12 2004; 311 2002; 120 2002; 20 1989; 245 2009; 71 2006; 49 1993; 10 2010; 135 1999; 274 2005; 449 1995; 268 2009; 5 1999; 276 1999; 277 2005; 2 2008; 133 1991; 325 2001; 114 2009; 106 12161441 - J Biol Chem. 2002 Oct 4;277(40):37235-41 20501743 - Mol Pharmacol. 2010 Sep;78(3):411-8 2475911 - Science. 1989 Sep 8;245(4922):1066-73 11427704 - Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8119-23 18218832 - J Pharmacol Exp Ther. 2008 Apr;325(1):77-88 19131639 - Am J Respir Cell Mol Biol. 2009 Sep;41(3):261-70 16821771 - J Med Chem. 2006 Jul 13;49(14):4098-115 16410244 - J Biol Chem. 2006 Mar 17;281(11):7392-8 15858812 - Pediatr Pulmonol. 2005 Oct;40(4):279-84 19883461 - Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254 8597960 - Nat Med. 1996 Apr;2(4):467-9 8361390 - Membr Biochem. 1993 Apr-Jun;10(2):107-18 17350348 - Auton Neurosci. 2007 Apr 30;133(1):35-54 12462 - Mol Pharmacol. 1976 Nov;12(6):945-57 12087134 - Physiol Rev. 2002 Jul;82(3):735-67 647157 - Br J Pharmacol. 1978 May;63(1):139-49 2157983 - N Engl J Med. 1990 Apr 26;322(17):1189-94 9620916 - Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1844-9 16443646 - Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1117-30 10516209 - Am J Physiol. 1999 Oct;277(4 Pt 1):L694-9 10543294 - Eur Respir J. 1999 Sep;14(3):693-6 16636206 - J Gen Physiol. 2006 May;127(5):591-604 11435221 - Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L458-68 14761879 - Am J Physiol Cell Physiol. 2004 Mar;286(3):C465-74 18928407 - Annu Rev Physiol. 2009;71:361-79 1762061 - J Pharmacol Exp Ther. 1991 Dec;259(3):1050-8 16150931 - Mol Pharmacol. 2005 Dec;68(6):1736-46 19156256 - Mol Biosyst. 2009 Feb;5(2):123-7 1377492 - Biochim Biophys Acta. 1992 Jun 11;1107(1):179-85 11739639 - J Cell Sci. 2001 Nov;114(Pt 22):4073-81 12927873 - Bioorg Med Chem. 2003 Sep 1;11(18):4113-20 1380673 - Nature. 1992 Aug 27;358(6389):761-4 19233902 - Am J Physiol Lung Cell Mol Physiol. 2009 May;296(5):L811-24 7537452 - Am J Physiol. 1995 Apr;268(4 Pt 1):C886-93 17338914 - Curr Top Dev Biol. 2007;78:23-46 3465558 - Eur J Respir Dis Suppl. 1986;146:319-26 11096079 - J Biol Chem. 2001 Mar 16;276(11):8306-13 20883477 - Br J Pharmacol. 2011 Jan;162(2):508-20 12548398 - Pflugers Arch. 2003 Jan;445(4):513-21 2169195 - Am J Physiol. 1990 Sep;259(3 Pt 1):C450-4 16127463 - J Clin Invest. 2005 Sep;115(9):2564-71 18339790 - Chest. 2008 Jun;133(6):1388-96 11514581 - J Biol Chem. 2001 Nov 2;276(44):41288-92 12503702 - Eur Respir J. 2002 Dec;20(6):1444-8 15517342 - Pflugers Arch. 2005 Feb;449(5):470-8 10199813 - Am J Physiol. 1999 Apr;276(4 Pt 1):C827-37 19190233 - J Pharmacol Exp Ther. 2009 May;329(2):764-74 15921678 - Eur J Pharmacol. 2005 Jun 1;516(2):118-24 12149280 - J Gen Physiol. 2002 Aug;120(2):191-201 12183642 - J Pharmacol Exp Ther. 2002 Sep;302(3):871-80 10488073 - J Biol Chem. 1999 Sep 24;274(39):27415-25 8048545 - Am J Physiol. 1994 Jul;267(1 Pt 1):L79-84 17998363 - Chest. 2007 Nov;132(5):1631-6 12475759 - Am J Physiol Cell Physiol. 2003 Jan;284(1):C2-15 15213059 - Am J Physiol Cell Physiol. 2004 Nov;287(5):C1173-83 15077107 - Nat Med. 2004 May;10(5):487-93 1857389 - N Engl J Med. 1991 Aug 22;325(8):533-8 14534336 - N Engl J Med. 2003 Oct 9;349(15):1433-41 19846789 - Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30 15148241 - Br J Pharmacol. 2004 Jun;142(3):531-42 9875854 - Cell. 1998 Dec 23;95(7):1005-15 11404240 - Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L16-23 16421364 - N Engl J Med. 2006 Jan 19;354(3):229-40 19454284 - Gastroenterology. 2009 Sep;137(3):976-85 11262417 - J Biol Chem. 2001 Jun 8;276(23):19723-8 15273255 - J Pharmacol Exp Ther. 2004 Dec;311(3):929-38 12832418 - J Biol Chem. 2003 Sep 12;278(37):35079-85 16196493 - Mol Pharm. 2005 Sep-Oct;2(5):407-13 20421370 - J Gen Physiol. 2010 May;135(5):399-414 7512555 - J Biol Chem. 1994 Apr 15;269(15):10983-6 17446337 - Am J Respir Crit Care Med. 2007 Aug 15;176(4):362-9 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_60_1 e_1_2_7_62_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_64_1 Ballard ST (e_1_2_7_5_1) 1994; 267 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_66_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_68_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_49_1 e_1_2_7_28_1 Cuthbert AW (e_1_2_7_17_1) 1976; 12 Devor DC (e_1_2_7_22_1) 1999; 276 e_1_2_7_73_1 e_1_2_7_50_1 e_1_2_7_71_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_54_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_56_1 e_1_2_7_37_1 e_1_2_7_58_1 e_1_2_7_39_1 Kohler D (e_1_2_7_44_1) 1986; 146 e_1_2_7_6_1 e_1_2_7_8_1 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_61_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_63_1 e_1_2_7_12_1 e_1_2_7_65_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_67_1 e_1_2_7_48_1 e_1_2_7_69_1 e_1_2_7_27_1 e_1_2_7_29_1 Dormer RL (e_1_2_7_24_1) 2001; 114 e_1_2_7_72_1 e_1_2_7_51_1 e_1_2_7_70_1 e_1_2_7_30_1 e_1_2_7_53_1 e_1_2_7_32_1 e_1_2_7_55_1 e_1_2_7_74_1 Roberts M (e_1_2_7_57_1) 1991; 259 e_1_2_7_34_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_59_1 e_1_2_7_38_1 Alexander SPH (e_1_2_7_4_1) 2009; 158 Accurso FJ (e_1_2_7_2_1) 2008; 31 |
| References_xml | – volume: 115 start-page: 2564 year: 2005b end-page: 2571 article-title: Small molecule correctors of defective ΔF508‐CFTR cellular processing identified by high‐throughput screening publication-title: J Clin Invest – volume: 276 start-page: 41288 year: 2001 end-page: 41292 article-title: Aquaporin‐5 dependent fluid secretion in airway submucosal glands publication-title: J Biol Chem – volume: 137 start-page: 976 year: 2009 end-page: 985 article-title: Activation of intestinal chloride secreion by lubprostone requires the cystic fibrosis transmembrane conductance regulator publication-title: Gastroenterology – volume: 132 start-page: 1631 year: 2007 end-page: 1636 article-title: Sodium channels and cystic fibrosis publication-title: Chest – volume: 114 start-page: 4073 year: 2001 end-page: 4081 article-title: Correction of delF508‐CFTR activity with benzo(c) quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells publication-title: J Cell Sci – volume: 277 start-page: 37235 year: 2002 end-page: 37241 article-title: High‐affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high‐throughput screening publication-title: J Biol Chem – volume: 78 start-page: 23 year: 2007 end-page: 44 article-title: Regulation of the epithelial Na channel by peptidases publication-title: Curr Top Dev Biol – volume: 322 start-page: 1189 year: 1990 end-page: 1194 article-title: A pilot study of aerosolised amiloride for the treatment of lung disease in cystic fibrosis publication-title: N Engl J Med – volume: 281 start-page: L458 year: 2001 end-page: L468 article-title: An optical method for quantifying rates of mucus secretion from single submucosal glands publication-title: Am J Physiol – volume: 284 start-page: C2 year: 2003 end-page: C15 article-title: Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease publication-title: Am J Physiol – volume: 133 start-page: 1388 year: 2008 end-page: 1396 article-title: Inhaled mannitol improves lung function in cystic fibrosis publication-title: Chest – volume: 259 start-page: 1050 year: 1991 end-page: 1058 article-title: Stimulation of sodium transport by duramycin in cultured human colonic epithelia publication-title: J Pharmacol Exp Ther – volume: 146 start-page: 319 year: 1986 end-page: 326 article-title: Inhalation of amiloride improves the mucociliary clearance and the cough clearance in patients with cystic fibroses publication-title: Eur J Respir Dis – volume: 5 start-page: 8 year: 2009 end-page: 27 article-title: New genetic and pharmacological treatments for cystic fibrosis publication-title: Curr Ped Rev – volume: 445 start-page: 513 year: 2003 end-page: 521 article-title: cAMP‐dependent activation of CFTR inhibits epithelial sodium channel (ENaC) without affecting its surface expression publication-title: Eur J Physiol – volume: 276 start-page: 8306 year: 2001 end-page: 8313 article-title: ClC‐2 contributes to native chloride secretion by a human intestinal cell line Caco‐2 publication-title: J Biol Chem – volume: 157 start-page: 1844 year: 1998 end-page: 1849 article-title: Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis publication-title: Am J Respir Crit Care Med – volume: 358 start-page: 761 year: 1992 end-page: 764 article-title: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature‐sensitive publication-title: Nature – volume: 120 start-page: 191 year: 2002 end-page: 201 article-title: Synergistic activation of ENaC by three membrane‐bound channel‐activating serine proteases (mCAP1, mCAP2, and mCAP3) and serum and glucocorticoid‐regulated kinase(Sgk1) in Xenopus oocytes publication-title: J Gen Physiol – volume: 133 start-page: 35 year: 2007 end-page: 54 article-title: Parasympathetic control of airway submucosal glands: Central reflexes and the airway intrinsic nervous system publication-title: Autonom Neurosci – volume: 78 start-page: 411 year: 2010 end-page: 418 article-title: A chemical corrector modifies the channel function of F508del‐CFTR publication-title: Mol Pharmacol – volume: 106 start-page: 18825 year: 2009 end-page: 18830 article-title: Rescue of a CF airway epithelial cell function in vitro by a CFTR potentiator, VX‐770 publication-title: Proc Nat Acad Sci USA – volume: 68 start-page: 1736 year: 2005a end-page: 1746 article-title: Antihypertensive 1,4‐dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations publication-title: Mol Pharmacol – volume: 286 start-page: C465 year: 2004 end-page: C474 article-title: Drug discovery in academe publication-title: Am J Physiol – volume: 5 start-page: 123 year: 2009 end-page: 127 article-title: Assessment of the CFTR and ENaC association publication-title: Mol Biosyst – volume: 325 start-page: 77 year: 2008 end-page: 88 article-title: Pharmacological properties of N‐(3,5‐diamino‐6‐chloropyrazine‐2‐carbonyl)N'‐4‐[4(2,3‐dihydroxypropoxy)phenyl]butyl‐guanidine methanesulphonate (552‐02), a novel epithelial sodium channel blocker with a potential clinical efficacy for cystic fibrosis lung disease publication-title: J Pharmacol Exp Ther – volume: 311 start-page: 929 year: 2004 end-page: 938 article-title: Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease publication-title: J Pharmacol Exp Ther – volume: 2 start-page: 467 year: 1996 end-page: 469 article-title: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations publication-title: Nat Med – volume: 449 start-page: 470 year: 2005 end-page: 478 article-title: Increase in intracellular Cl concentration by cAMP and Ca ‐dependent stimulation of M1 collecting duct cells publication-title: Eur J Physiol – volume: 142 start-page: 531 year: 2004 end-page: 542 article-title: 4‐chloro‐benzo{F]isoquinoline (CBIQ) activates CFTR chloride channels and KCNN4 potassium channels in human airway epithelial cells publication-title: Br J Pharmacol – volume: 135 start-page: 5399 year: 2010 end-page: 5414 article-title: Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel publication-title: J Gen Physiol – volume: 325 start-page: 533 year: 1991 end-page: 538 article-title: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis publication-title: N Engl J Med – volume: 296 start-page: L811 year: 2009 end-page: L824 article-title: Lubiprostone stimulates secretion from tracheal submucosal glands of sheep,pigs and humans publication-title: Am J Physiol – volume: 259 start-page: C450 year: 1990 end-page: C454 article-title: Duramycin enhances chloride secretion in airway epithelium publication-title: Am J Physiol – volume: 290 start-page: L1117 year: 2006 end-page: L1130 article-title: Rescue of ΔF508‐CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules publication-title: Am J Physiol – volume: 274 start-page: 27415 year: 1999 end-page: 27425 article-title: Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel publication-title: J Biol Chem – volume: 98 start-page: 8119 year: 2001 end-page: 8123 article-title: Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na ] and pH but elevated viscosity publication-title: Proc Natl Acad Sci USA – volume: 281 start-page: 7392 year: 2006 end-page: 7398 article-title: Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands publication-title: J Biol Chem – volume: 329 start-page: 764 year: 2009 end-page: 774 article-title: Camostat attenuates airway epithelial sodium channel function in vivo through inhibition of a channel‐activating protease publication-title: J Pharmacol Exp Ther – volume: 281 start-page: L16 year: 2001 end-page: L23 article-title: Na transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39‐9437 publication-title: Am J Physiol – volume: 245 start-page: 1066 year: 1989 end-page: 1073 article-title: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA publication-title: Science – volume: 268 start-page: 886 year: 1995 end-page: 893 article-title: cAMP independent inactivation of CFTR chloride channels by the tyrosine kinase inhibitor genistein publication-title: Am J Physiol – volume: 278 start-page: 35079 year: 2003 end-page: 35085 article-title: Nanomolar affinity small molecule correctors of defective ΔF508‐CFTR chloride channel gating publication-title: J Biol Chem – volume: 302 start-page: 871 year: 2002 end-page: 880 article-title: Pharmacology of INS37217 [P ‐(uridine 5′)‐P ‐92‐deoxycytidine 5′) tetraphosphate, tetrasodium salt], a next‐generation P2Y receptor agonist for the treatment of cystic fibrosis publication-title: J Pharmacol Exp Ther – volume: 176 start-page: 362 year: 2007 end-page: 369 article-title: Phase 2 randomised safety and efficacy tial of nebulized Denufosol tetrasodium in cystic fibrosis publication-title: Am J Respir Crit Care Med – volume: 276 start-page: C827 year: 1999 end-page: C837 article-title: UTP inhibits Na absorption in wild‐type and ΔF508 CFTR‐expressing human bronchial epithelia publication-title: Am J Physiol – volume: 162 start-page: 508 year: 2010 end-page: 520 article-title: Lubiprostone targets prostanoid EP receptors in ovine airways publication-title: Br J Pharmacol – volume: 269 start-page: 10983 year: 1994 end-page: 10986 article-title: The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel publication-title: J Biol Chem – volume: 49 start-page: 4098 year: 2006 end-page: 4115 article-title: Design,synthesis, and structure‐activity relationships of novel 2‐substituted pyrazinoylguanidine epithelial sodium channel blockers: Drugs for cystic fibrosis and chronic bronchitis publication-title: J Med Chem – volume: 277 start-page: L694 year: 1999 end-page: L699 article-title: CFTR involvement in chloride, bicarbonate, and liquid secretion by airway submucosal glands publication-title: Am J Physiol – volume: 276 start-page: 19723 year: 2001 end-page: 19728 article-title: Novel CFTR channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds publication-title: J Biol Chem – volume: 95 start-page: 1005 year: 1998 end-page: 1010 article-title: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease publication-title: Cell – volume: 127 start-page: 591 year: 2006 end-page: 604 article-title: Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia publication-title: J Gen Physiol – volume: 20 start-page: 1444 year: 2002 end-page: 1448 article-title: Hypertonic saline increases tight junction permeability in airway epithelium publication-title: Eur Respir J – volume: 1107 start-page: 179 year: 1992 end-page: 185 article-title: Ion channel formation by duramycin publication-title: Biochim Biophys Acta – volume: 287 start-page: C1173 year: 2004 end-page: C1183 article-title: SPI‐0211 activates T84 cell chloride transport and recombinant human ClC‐2 chloride currents publication-title: Am J Physiol – volume: 354 start-page: 229 year: 2006 end-page: 240 article-title: A controlled trial of long‐term inhaled hypertonic saline in patients with cystic fibrosis publication-title: N Engl J Med – volume: 10 start-page: 487 year: 2004 end-page: 493 article-title: Increased airway epithelial Na absorption produces cystic fibrosis‐like lung disease in mice publication-title: Nature Med – volume: 31 start-page: 295 year: 2008 article-title: Interim results of a phase 2a study of VX‐770 to evaluate safety, pharmacokinetics and biomarkers of CFTR activity in cystic fibrosis subjects with G551D publication-title: Pediatr Pulmonol Suppl – volume: 63 start-page: 139 year: 1978 end-page: 149 article-title: Effects of some pyrazine carboxamides on sodium transport in frog skin publication-title: Br J Pharmacol – volume: 349 start-page: 1433 year: 2003 end-page: 1441 article-title: Gentamicin‐induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations publication-title: N Engl J Med – volume: 267 start-page: 79 year: 1994 end-page: 84 article-title: Bioelectric properties of proximal bronchiolar epithelium publication-title: Am J Physiol – volume: 82 start-page: 735 year: 2002 end-page: 767 article-title: Epithelial sodium channel/degenerin family of ion channels: A variety of functions for a shared structure publication-title: Physiol Rev – volume: 41 start-page: 261 year: 2009 end-page: 270 article-title: Alpha 1‐antitrypsin inhibits epithelial Na transport and publication-title: Am J Respir Cell Mol Biol – volume: 11 start-page: 4113 year: 2003 end-page: 4120 article-title: Benzoflavone activators ot the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide‐binding domain publication-title: Bioorg Med Chem – volume: 516 start-page: 118 year: 2005 end-page: 124 article-title: Chlorobenzo[F]isoquinoline (CBIQ) a novel activator of CFTR and ΔF508 CFTR publication-title: Eur J Pharmacol – volume: 158 start-page: S1 issue: 1 year: 2009 end-page: S254 article-title: Guide to receptors and channels (GRAC), 4th edn publication-title: Br J Pharmacol – volume: 71 start-page: 361 year: 2009 end-page: 379 article-title: Activation of the epithelial sodium channel (ENaC) by serine proteases publication-title: Ann Rev Physiol – volume: 10 start-page: 107 year: 1993 end-page: 118 article-title: Duramycin increases intracellular calcium in airway epithelium publication-title: Membr Biochem – volume: 40 start-page: 279 year: 2005 end-page: 284 article-title: Cystic fibrosis and airway submucosal glands publication-title: Ped Pulmonol – volume: 14 start-page: 693 year: 1999 end-page: 696 article-title: The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis publication-title: Eur Respir J – volume: 12 start-page: 945 year: 1976 end-page: 957 article-title: Importance of guanidinium groups for blocking sodium channels in epithelia publication-title: Mol Pharmacol – volume: 2 start-page: 407 year: 2005 end-page: 413 article-title: Rescue of ΔF508 and other misprocessed CFTR mutants by a novel quinazoline compound publication-title: Mol Pharmaceut – ident: e_1_2_7_23_1 doi: 10.1378/chest.07-0288 – ident: e_1_2_7_16_1 doi: 10.1152/ajpcell.00528.2003 – ident: e_1_2_7_28_1 doi: 10.1124/jpet.104.071886 – ident: e_1_2_7_43_1 doi: 10.1056/NEJM199108223250802 – volume: 12 start-page: 945 year: 1976 ident: e_1_2_7_17_1 article-title: Importance of guanidinium groups for blocking sodium channels in epithelia publication-title: Mol Pharmacol contributor: fullname: Cuthbert AW – ident: e_1_2_7_33_1 doi: 10.1038/nm0496-467 – ident: e_1_2_7_70_1 doi: 10.1085/jgp.20028598 – ident: e_1_2_7_63_1 doi: 10.1038/sj.bjp.0705846 – ident: e_1_2_7_7_1 doi: 10.1074/jbc.274.39.27415 – ident: e_1_2_7_74_1 doi: 10.1124/jpet.102.035485 – ident: e_1_2_7_54_1 doi: 10.1172/JCI24898 – ident: e_1_2_7_64_1 doi: 10.1085/jgp.200509468 – ident: e_1_2_7_41_1 doi: 10.1152/physrev.00007.2002 – ident: e_1_2_7_13_1 doi: 10.3109/09687689309150258 – ident: e_1_2_7_19_1 doi: 10.1111/j.1476-5381.1978.tb07783.x – volume: 276 start-page: C827 year: 1999 ident: e_1_2_7_22_1 article-title: UTP inhibits Na+ absorption in wild‐type and ΔF508 CFTR‐expressing human bronchial epithelia publication-title: Am J Physiol doi: 10.1152/ajpcell.1999.276.4.C827 contributor: fullname: Devor DC – ident: e_1_2_7_8_1 doi: 10.1039/B810471A – ident: e_1_2_7_18_1 doi: 10.1111/j.1476-5381.2010.01058.x – ident: e_1_2_7_45_1 doi: 10.1007/s00424-002-0957-z – ident: e_1_2_7_58_1 doi: 10.1034/j.1399-3003.1999.14c32.x – ident: e_1_2_7_71_1 doi: 10.1056/NEJMoa022170 – ident: e_1_2_7_39_1 doi: 10.1074/jbc.M512766200 – ident: e_1_2_7_50_1 doi: 10.1016/S0092-8674(00)81724-9 – ident: e_1_2_7_14_1 doi: 10.2174/157339609787587555 – ident: e_1_2_7_3_1 doi: 10.1007/s00424-004-1356-4 – ident: e_1_2_7_25_1 doi: 10.1056/NEJMoa043900 – ident: e_1_2_7_72_1 doi: 10.1016/j.autneu.2007.01.008 – ident: e_1_2_7_34_1 doi: 10.1152/ajpcell.1995.268.4.C886 – ident: e_1_2_7_42_1 doi: 10.1056/NEJM199004263221704 – volume: 158 start-page: S1 issue: 1 year: 2009 ident: e_1_2_7_4_1 article-title: Guide to receptors and channels (GRAC), 4th edn publication-title: Br J Pharmacol contributor: fullname: Alexander SPH – ident: e_1_2_7_62_1 doi: 10.1016/S0968-0896(03)00435-8 – ident: e_1_2_7_31_1 doi: 10.1164/ajrccm.157.6.9709043 – ident: e_1_2_7_46_1 doi: 10.1165/rcmb.2008-0384OC – ident: e_1_2_7_21_1 doi: 10.1164/rccm.200608-1238OC – ident: e_1_2_7_37_1 doi: 10.1073/pnas.131087598 – ident: e_1_2_7_61_1 doi: 10.1074/jbc.M107257200 – volume: 259 start-page: 1050 year: 1991 ident: e_1_2_7_57_1 article-title: Stimulation of sodium transport by duramycin in cultured human colonic epithelia publication-title: J Pharmacol Exp Ther contributor: fullname: Roberts M – ident: e_1_2_7_12_1 doi: 10.1152/ajpcell.1990.259.3.C450 – ident: e_1_2_7_47_1 doi: 10.1021/mp0500521 – ident: e_1_2_7_48_1 doi: 10.1074/jbc.M205932200 – ident: e_1_2_7_67_1 doi: 10.1073/pnas.0904709106 – ident: e_1_2_7_30_1 doi: 10.1124/jpet.107.130443 – ident: e_1_2_7_11_1 doi: 10.1124/mol.110.065862 – ident: e_1_2_7_69_1 doi: 10.1152/ajpcell.00417.2002 – ident: e_1_2_7_9_1 doi: 10.1053/j.gastro.2009.05.037 – volume: 146 start-page: 319 year: 1986 ident: e_1_2_7_44_1 article-title: Inhalation of amiloride improves the mucociliary clearance and the cough clearance in patients with cystic fibroses publication-title: Eur J Respir Dis contributor: fullname: Kohler D – ident: e_1_2_7_51_1 doi: 10.1074/jbc.M006764200 – ident: e_1_2_7_35_1 doi: 10.1002/ppul.20183 – ident: e_1_2_7_6_1 doi: 10.1152/ajplung.1999.277.4.L694 – volume: 31 start-page: 295 year: 2008 ident: e_1_2_7_2_1 article-title: Interim results of a phase 2a study of VX‐770 to evaluate safety, pharmacokinetics and biomarkers of CFTR activity in cystic fibrosis subjects with G551D publication-title: Pediatr Pulmonol Suppl contributor: fullname: Accurso FJ – ident: e_1_2_7_68_1 doi: 10.1152/ajpcell.00397.2003 – ident: e_1_2_7_15_1 doi: 10.1124/jpet.108.148155 – ident: e_1_2_7_26_1 doi: 10.1074/jbc.M101892200 – ident: e_1_2_7_49_1 doi: 10.1038/nm1028 – ident: e_1_2_7_29_1 doi: 10.1021/jm051134w – ident: e_1_2_7_38_1 doi: 10.1152/ajplung.2001.281.2.L458 – ident: e_1_2_7_66_1 doi: 10.1152/ajplung.00169.2005 – ident: e_1_2_7_59_1 doi: 10.1146/annurev.physiol.010908.163108 – ident: e_1_2_7_20_1 doi: 10.1038/358761a0 – ident: e_1_2_7_65_1 doi: 10.1085/jgp.201010399 – ident: e_1_2_7_73_1 doi: 10.1074/jbc.M303098200 – ident: e_1_2_7_53_1 doi: 10.1124/mol.105.015149 – volume: 114 start-page: 4073 year: 2001 ident: e_1_2_7_24_1 article-title: Correction of delF508‐CFTR activity with benzo(c) quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells publication-title: J Cell Sci doi: 10.1242/jcs.114.22.4073 contributor: fullname: Dormer RL – ident: e_1_2_7_27_1 doi: 10.1016/S0021-9258(19)78079-X – ident: e_1_2_7_10_1 doi: 10.1152/ajplung.2001.281.1.L16 – volume: 267 start-page: 79 year: 1994 ident: e_1_2_7_5_1 article-title: Bioelectric properties of proximal bronchiolar epithelium publication-title: Am J Physiol contributor: fullname: Ballard ST – ident: e_1_2_7_56_1 doi: 10.1126/science.2475911 – ident: e_1_2_7_55_1 doi: 10.1016/S0070-2153(06)78002-4 – ident: e_1_2_7_32_1 doi: 10.1183/09031936.02.00017202 – ident: e_1_2_7_60_1 doi: 10.1016/0005-2736(92)90345-M – ident: e_1_2_7_36_1 doi: 10.1378/chest.07-2294 – ident: e_1_2_7_40_1 doi: 10.1152/ajplung.90636.2008 – ident: e_1_2_7_52_1 doi: 10.1016/j.ejphar.2005.04.037 |
| SSID | ssj0014775 |
| Score | 2.3339632 |
| SecondaryResourceType | review_article |
| Snippet | Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a... |
| SourceID | pubmedcentral proquest crossref pubmed wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 173 |
| SubjectTerms | airway surface liquid Animals CFTR Clinical trials Clinical Trials as Topic Cystic fibrosis Cystic Fibrosis - drug therapy Cystic Fibrosis - genetics Cystic Fibrosis - metabolism Cystic Fibrosis Transmembrane Conductance Regulator - genetics Cystic Fibrosis Transmembrane Conductance Regulator - metabolism epithelial chloride ion channels epithelial sodium ion channels high throughput screening Humans Medical research Molecular Targeted Therapy Mutation Reviews |
| SummonAdditionalLinks | – databaseName: Wiley-Blackwell dbid: 33P link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T-QwEB4BFQ3P4y685AJRERSvnyl5akWBVgIkOsuOY7FNciK30i2_nnGyG9iDAp3oIjkve_x5vrHHnwGOCi-DV5lGpIk85RbjFMcoTb0L1Dlvw8DGQHF4p24f9eVVlMm5me-F6fQh-gm3iIx2vI4At675B-RKpghYOsvQopSp08gnMWhod3OwUb-gwJXqDjOImohU68Wknk9ftOipPtDPj1mU79lt656u17-zYhuwNiOp5KzrVZuwVFZbcDzqVK6nJ-T-bdNWc0KOyehN_3q6DRkOnOSpfh6_YI8m44ogxyR9QjupAymmUR2aBPzNuhk3P-Dh-ur-YpjODmZICxG9muTBIo6FxQ7AtHTByQJNrfMsyEx7pWXIfF7QjAmLDCeUBdJEb2ngpUJ-49kOrFR1Vf4CIrjjtBDOCec557kuBk7l5UDlgZVBiATo3Ajmd6e_Yd7HLUqa2FAmNpRpG8r8TWB_bi0zQ2RjIm_iOfbKPAHSFyOW4gKJrcp60hiNdA8HKc0S-NnZtv9mjJO1ZDQBtWD1_oYo071YUo2fWrluhqwWfU4CsrX6l6thzkfDeLX7vw_uwWo3Ax7TM_dh5c_zpDyA5cZPDltwvALD1gwS priority: 102 providerName: Wiley-Blackwell |
| Title | New horizons in the treatment of cystic fibrosis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1476-5381.2010.01137.x https://www.ncbi.nlm.nih.gov/pubmed/21108631 https://www.proquest.com/docview/1554497089 https://search.proquest.com/docview/861205183 https://pubmed.ncbi.nlm.nih.gov/PMC3085876 |
| Volume | 163 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ja9wwFH50cuqldK_TNOgQcooz1mj1MStTQouhKfQmLMkihsYOcQc6_fV98jLJkEvpxRhkkP0W6XvWp08AB87L4FWmMdNEnvIS6xTLKE29DdRaX4ZFGQvF5Tf19Yc-v4gyOWLaC9OT9p2tj5uft8dNfdNzK-9u3Xziic2LL2cMcQJm8XwGM8SGU4k-Lh1wpYZjC6L6IdV6m77DlUwxx-lI6qKUqV6LOtZBWjK6PT09wZxPqZOPIW0_J12-hBcjmCQnw0u_gmdV8xoOi0GNen1Erh82V3VH5JAUDzrV6zeQ4QBHbtr7-g9GHqkbgliQbIjnpA3EraOKMwlYUrdd3b2F75cX12fLdDxAIXUizj6ShxLzTZToKKalDVY6dInOsyAz7ZWWIfO5oxkTJSKRUDmEc76kgVcKcYhn72CnaZvqAxDBLadOWCus55zn2i2syquFygOrghAJ0Mlu5m7QyTCP6wslTTS7iWY3vdnN7wT2JgObMXM6E_ENzzF68gTIphljPi5klE3VrjqjEZbhYKJZAu8Hd2z6nPyYgNpy1OaBKKe93YJR1stqj1GVgOxd-s-fYU6LZbzb_e8uP8Lz4Vd15FHuwc6v-1X1CWadX-3DjLECr-efr_b7OP8LADP6XQ |
| link.rule.ids | 230,315,729,782,786,887,1408,27933,27934,46064,46488,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB619NBe2tIHpKXgA-JEqnj9zLEP0CIoWomt1JsVx7HYS4JIV2L59Z1JdgNbeqiq3iI5L3vm83y2x58B9sugYzCZRaSpPJUFjlO84DwNPnLvQxFHBQ0Uxxfm_If9ekQyOaervTC9PsQw4UbI6PprAjhNSP-GcqNTRCxfpmhxLsxHJJRPpEa_pP0cYjIsKUhj-uMMSBWRW7ue1vPHN63HqgcE9GEe5X1-2wWo4xf_tWov4fmSp7JPvWNtwqOqfgUHk17oenHIpnf7ttpDdsAmdxLYi9eQYd_JLpvr2S06NZvVDGkmG3LaWRNZuSCBaBbxP5t21r6B78dH0y_jdHk2Q1oqCmxaxgKhrAr0AWG1j16XaG2bZ1FnNhirYxbykmdCFUhyYlUiUwwFj7IySHGCeAsbdVNX28CU9JKXynvlg5Qyt-XIm7wamTyKKiqVAF9ZwV31Ehzu_tDFaEcN5aihXNdQ7iaBnZW53BKUrSPqJHN0zDwBNhQjnGiNpKirZt46i4wP-ykrEtjqjTt8k4bKVguegFkz-3ADKXWvl9Szy06xWyCxxbCTgO7M_tfVcJ8nY7p6968P7sHT8fTbmTs7OT99D8_6CXHK1tyBjZ_X8-oDPG7DfLdDyi-_4RA6 |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwEB21W6nqpVBoaWBbfECcSBWvP3OkhdWWVigSVOrNiuNYu5cEEVZi-fWMk93AQg9V1Vsk58seP88be_wMcFA46Z1KNCJNpDHPMU6xjNLYWU-tdbkf5SFQnFyo89_65DTI5Jyt9sJ0-hD9hFtARjteB4BfOf8E5ErGCFi6zNCilKkvyCdfcWTlQUefsaxfUeBKdacZBFFEqvV6Vs8f37Tuqp7xz-dplI_pbeufxhv_s2ab8HbJUslx163ewYuy2oLDrJO5XhyRy4ddW80ROSTZgwD2YhsSHDnJtL6e3WGXJrOKIMkkfUY7qT0pFkEemnj8zbqZNe_h1_j08tskXp7MEBciuDXJfY5AFjn2AKal9VYWaGudJl4m2iktfeLSgiZM5EhxfFkgT3Q59bxUSHAc-wCDqq7Kj0AEt5wWwlphHec81cXIqrQcqdSz0gsRAV0ZwVx1AhzmceCipAkNZUJDmbahzG0Ew5W1zBKSjQnEiafYLdMISF-MYAorJHlV1vPGaOR7OEppFsFOZ9v-myFQ1pLRCNSa1fsbgk73ekk1m7Z63QxpLTqdCGRr9b-uhvmaTcLV7r8-uA-vs5Ox-fn9_McevOlmw0Oq5hAGN9fz8hO8bNz8c4uTe1ErDuA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+horizons+in+the+treatment+of+cystic+fibrosis&rft.jtitle=British+journal+of+pharmacology&rft.au=Cuthbert%2C+AW&rft.date=2011-05-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0007-1188&rft.eissn=1476-5381&rft.volume=163&rft.issue=1&rft.spage=173&rft.epage=183&rft_id=info:doi/10.1111%2Fj.1476-5381.2010.01137.x&rft.externalDBID=10.1111%252Fj.1476-5381.2010.01137.x&rft.externalDocID=BPH1137 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon |